The Omega-TTM Advantage
Additional References
Cardiovascular Benefits Section.
Kromhout D, Bosschieter EB, Coulander CDL. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985; 312:1205-09
Shekell RB, Missell LV, Paul O, et al. Fish consumption and mortality from coronary heart disease. N Engl J Med 1985; 313:820
Norell SE, Ahlbom A, Feychting M, et al. Fish consumption and mortality from coronary heart disease. BMJ 1986; 293:426
Knapp HR, FitzGerald GA. The antihypertensive effects of fish oil: a controlled study of polyunsaturated fatty acid supplements in essential hypertension. N Engl J Med 1989; 320:1037-43
Bonaa KH, Bjerve KS, Straume B, et al. Effect of eicosapentaenoic and docosahexaenoic acids on blood pressure in hypertension: a population-based intervention trial from the Tromso study. N Engl J Med 1990; 322:795-801
Radack K, Deck C, Huster G. The effects of low doses of n-3 fatty acid supplementation on blood pressure in hypertensive subjects: a randomized controlled trial. Arch Intern Med 1991; 151:1173-80
Coenzyme Q10 Section.
Bliznakov EG. The Miracle Nutrient Coenzyme Q10. Bantam Books, New York, 1987.
Bliznakov EG, Wilkins DJ. Biochemical and clinical consequences of coenzyme Q10 biosynthesis by lipid-lowering HMG-CoA reductase inhibitors (statins): A critical review. Adv Therap 1998;15:218-28.
Bliznakov, E. G. Lipid-lowering drugs (statins), cholesterol and coenzyme Q10. The Baycol case - a modern Pandora's box. Biomed. Pharmacother., 56, 56, 2002.
Crane, F. L. New functions for coenzyme Q. Protoplasma, 213, 127, 2000.
Crane FL, Hatefi Y, Lester RL, Widmer C. Isolation of a quinone from beef heart mitochondria. Biochim Biophys Acta 1957;25:220-1.
Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995;1271:195-204.
Fuke C, Krikorian SA, Couris RR. Coenzyme Q10: A review of essential functions and clinical trials. US Pharmacist 2000;25:1-12.
Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc Nat Acad Sci (USA) 1985;82:4240-4.
Langsjoen PH, Langsjoen AM. Coenzyme Q10 in cardiovascular disease with emphasis on heart failure and myocardial ischemia. Asia Pacific Heart J. 1998; 7:160-8.
Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. Biofactors 1999;9:273-84.
Mortensen SA, Vadhanavikit S, Baandrup U, Folkers K. Long-term coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure. Drugs Exp Clin Res 1985;11:581-93.
Sinatra ST. The Coenzyme Q10 Phenomenon. Keats Publishing, New Canaan, 1998.
Shults C. W., Oakes, D., Kieburtz, K., Beal, M. F., Haas, R., Plumb, S., Juncos, J. L., Nutt, J., Shoulson, I., Carter, J., Kompoliti, K., Perlmutter, J. S., Reich, R., Stern, M., Watts, R. L., Kurlan, R., Molho, E., Harrison, M., Lew, M. and the Parkinson Study group. Effect of coenzyme Q10 in early Parkinson disease. Evidence of slowing of the functional decline. Arch. Neurol., 59, 1541, 2002.
Wolf, D. E., Hoffman, C. H., Trenner, N. R., Arison, B. H., Shunk, C. H., Linn, B. D., McPherson, J. F. and Folkers, K. Structure studies on the coenzyme Q group. J. Am. Chem. Soc., 80, 4752, 1958.
Yamamura Y, Ishiyama T, Yamagami T et al. Clinical use of coenzyme Q for treatment of cardiovascular disease. Jap. Circ. J., 1967;31:168.